Particularly, MK-1775 enhances the efficacy of SRC inhibitors in BL [45], and the combination of CHK1 and WEE-1 inhibitors is synergistic in mantle cell lymphoma [46]. This evidence concerns the gene WEE1 and Burkitt lymphoma.